Trial reportEndocrine2025
Mediterranean diet, selenium and Graves' ophthalmopathy: a prospective, randomized, single-center study.
Trial report in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Micronutrients in Autoimmune Diseases: Shining a Light on Vitamin D, Cobalamin, Folate, and Iron Metabolism.Nutrients · 2026Review
- Comparison of the 2021 EUGOGO guidelines and the 2022 ATA/ETA consensus statement for the management of Graves' orbitopathy.European thyroid journal · 2025Review
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeGraves' ophthalmopathy (GO) is an autoimmune-inflammatory condition affecting about 25% of patients with Graves' disease (GD). Oxidative stress (OS) increases the production of inflammatory cytokines, the production of free radicals (ROS) and insulin resistance modulating IGF-1r/TSHr cross-talk in GO. Selenium is a component of selenoproteins and promotes the suppression of ROS production. We aim to evaluate the effects of the Mediterranean diet (MD) naturally enriched with selenium in patients with GD and active mild GO on thyroid function parameters, nutritional state, autoimmunity and the clinical course of GO.
methods40 GD patients with untreated mild active GO and stable thyroid function were randomly assigned to the Mediterranean diet (MD) naturally enriched with selenium (MD group) or a free diet (FD group). The selenium content of the MD was increased by approximately 30% according to the reference levels of nutrient and energy intake for the Italian population (LARN 2014). The combined endocrinological-ophthalmological evaluation was carried - out at baseline and after 12 and 24 weeks from the beginning of the MD or FD.
resultsThe MD contained 178.1 ± 15.1 mcg of SE, and the diet was balanced with respect to the macronutrient composition. The Clinical Activity Score (CAS) improved significantly at visit 1 in the MD group compared to the FD group (p = 0.03). Hertel measurements and eyes motility were not different at visits 1 and 2 in either group of patients. Soft tissue involvement improved in the MD group compared to the FD group at visit 1 and 2 (p = 0.03 and 0.04). The absolute value (mm) of the eyelid aperture was significantly lower at visit 2 in the MD group than in the FD group (9.3 ± 0.6 vs. 10.5 ± 0.5, p = 0.01). The relative change in BMI was significantly lower in the MD group than in the FD group at visit 2 (2.5 [(-9.4) -10.1)] vs. 5.1 [(-0.4) -15)] kg, p = 0.04). TRABs values and thyroid function did not differ and decreased to a similar degree in both groups of patients during the observation period. No cases of GO exacerbation were observed in the two groups of patients.
conclusionsThe MD is a versatile dietary style and should be a component of the dietary treatment plan in patients with GD and mild GO to reduce weight regain and the inflammation and insulin resistance, which in turn contribute to the autoimmune-inflammatory processes of GO.
Indexed as
Identifiers
40707809What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.